Boston Scientific Launches GUIDE ™ XT System for Deep Brain Stimulation Visualization in Europe
Thursday, September 27, 2018
Boston Scientific Corporation today announced the European launch of the GUIDE ™ XT System for Deep Brain Stimulation (SCP) Visualization. GUIDE XT is the first SCP visualization system designed with directionality in mind using anatomy modeling and patient specific stimulation field. This technology provides physicians with 3D image planning options, as well as personalization and optimization of SCP processing - when used in conjunction with SCP's Vercise ™ system.
CPA treats the symptoms of movement disorders in patients with Parkinson's disease, dystonia or essential tremor. The procedure stimulates a targeted region of the brain through electrodes powered by a device called an Implantable Pulse Generator (GII).
The GUIDE XT system automatically detects the placement of electrodes, implanted by a neurosurgeon, on brain imaging. After placement of the electrodes, a clinician schedules the patient's device so that the GUIDE XT system can visualize the stimulation field and efficiently determine the most appropriate parameters for each patient.
"As part of the current PCS programming practice, multiple consultations as well as trial and error times are needed to identify appropriate pacing parameters. Explained Professor Jens Volkmann, Director and Chair of the Neurology Department at the University Hospital Wurzburg , Germany. "Unlike visualization systems using a generic atlas, the GUIDE XT system allows us to visualize the position of the electrodes in the patient's brain. By simulating and visualizing different stimulation parameters, it is much easier to develop an initial program that can produce positive results in a given patient."
"Direct visualization of relevant structures in a patient's brain is very important for the CPS. It serves as a reference for planning the surgical trajectory for implanting electrodes. Says Professor Ludvic Zrinzo, Head of Functional Neurosurgery at the University College of London , Queen Square , London. "XT GUIDE integrates surgical planning with radiological verification of electrode placement. This facilitates workflow and allows surgeons to more effectively assist their clinical colleagues in programming SCP settings for each patient. "
One study found that the overall programming time using the first-generation GUIDE system was significantly shorter than the traditional programming time (n =0, p <0.0001) 1 . Reduced programming time is beneficial to both the physician and the patient as it eliminates the need for additional consultations and reduces the lengthy delays required to adjust stimulation parameters that can be stressful and tiring.
"The GUIDE XT system is designed to simplify PCS programming by providing physicians with personalized and complementary information that could lead to better outcomes for patients. Said Maulik Nanavaty, deputy general manager and president of the neuromodulation division at Boston Scientific. "Boston Scientific is dedicated to providing advanced solutions and significant innovations to help clinicians improve the lives of patients through personalized treatments. "
Since obtaining the CE mark for SCP's Vercise system in 2012, Boston Scientific has maintained a constant pace of innovation in the field of PCS, most notably illustrated by the launch in 2017 of SCP * 's Vercise Gevia ™ system. Cartesia ™ directional electrodes ** featuring a rechargeable magnetic resonance (MR) system 2 with directionality capabilities. The company also launched SCP's Vercise system in the United States late last year.
GUIDE XT ** was developed in partnership with Brainlab AG, a company dedicated to software-driven medical technology that helps improve patient treatment planning and surgical navigation. The exclusive collaboration between Brainlab and Boston Scientific has a comprehensive portfolio covering all key elements of deep brain stimulation (PCS) treatment for both patients and physicians.
About Boston Scientific
Boston Scientific is transforming lives with innovative medical solutions that improve the health of patients around the world. Its position as a world leader in medical technology for more than 35 years enables it to advance science for the benefit of life by providing a wide range of high-performance solutions that address the unmet needs of patients and reduce the cost of patient care. health. For more information, please visit www.bostonscientific.eu and log in to the company's Twitter and Facebook accounts .
Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933 andSection 21E of the Securities Exchange Act of 1934, which can be identified by the use of words such as "anticipate," "expect," "plan," "believe," "plan," "estimate," "have," the intention of "and other similar terms. These forward-looking statements are based on our beliefs, assumptions and estimates, which use the information we have available to us at the relevant time, and should not be construed as guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the launch, performance and impact of our products. In the event that our assumptions prove to be incorrect, or if certain risks or uncertainties materialize, Actual results may vary materially from expectations and projections expressed or implied by our forward-looking statements. In some cases, these factors have altered and may, in the future (along with other factors), alter our ability to implement our corporate strategy, and could result in a significant divergence of actual results from those targeted by forward-looking statements in this press release. Accordingly, we caution the reader not to place undue reliance on any of our forward-looking statements. future (together with other factors) our ability to implement our business strategy, and could cause actual results to differ materially from those contemplated by the forward-looking statements in this release. Accordingly, we caution the reader not to place undue reliance on any of our forward-looking statements. future (together with other factors) our ability to implement our business strategy, and could cause actual results to differ materially from those contemplated by the forward-looking statements in this release. Accordingly, we caution the reader not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include: future regulatory, competitive, economic and repayment conditions, introduction of new products, demographic trends, closing and integration of acquisitions, intellectual property, litigation, the financial market situation and future business decisions made by our company or our competitors. It is difficult, if not impossible, to predict all of these factors in a precise way, and most of them are out of our control. For a list and description of these and other significant risks and uncertainties that may affect our future operations, see Part I, Section 1A "Risk Factors" in our last Annual Report on Form 10-K filed with the US Securities and Exchange Commission (SEC), which is available in Part II, Item 1A " Risk Factors "in the quarterly reports on Form 10-Q that we filed or will file at a later date. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or events, conditions or circumstances that underlie these expectations or that result in actual results that differ from those contained in forward-looking statements. This warning is applicable to the
CONTACTS
Rosie Ireland
Media Relations for EMEA ( Europe , Middle East, Africa)
+44 (0) 7585 403359
rosie.ireland@bsci.com
Susie Lisa, CFA
508-683-5565 (Office)
Investor Relations
Boston Scientific Corporation
BSXInvestorRelations@bsci.com
1 Pavese et al., Traditional trial-and-error versus neuroanatomical-3D-image software-assisted deep brain stimulation programming in patients with Parkinson's disease (2017), WSSFN Conference, Berlin .
2 MRI condition at 1.5 Tesla when all conditions of use are met.